Loading clinical trials...
Loading clinical trials...
Phase 1, Multiple dose Study of MPC-6827 in Subjects with Refractory Brain Metastases.
Keep your clinical trial research organized — questions to ask, what to expect, and key details.
Lead Sponsor
Myrexis Inc.
NCT05386108 · Breast Neoplasms, Brain Neoplasms, and more
NCT01638130 · Brain Neoplasms, Primary Malignant
NCT05267158 · Brain Metastases, Adult, Brain Neoplasms, Adult, Malignant
NCT07238322 · Retrospective Study, Glioma, and more
NCT07499141 · High Grade Glioma, Glioblastoma, and more
MD Anderson Cancer Center
Houston, Texas
Use Clareo to keep notes, questions, trial details, and next steps organized before and after appointments.
Start free trial →Data Source & Attribution
This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.
Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.
Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.
View ClinicalTrials.gov Terms and Conditions